Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial | Zendy

Guillaume MarquisGravel | Zendy; Matthew T. Roe | Zendy; Holly R. Robertson | Zendy; Robert A. Harrington | Zendy; Michael Pencina | Zendy; Lisa G. Berdan | Zendy; Bradley G. Hammill | Zendy; Madelaine Faulkner | Zendy; Daniel Muñoz | Zendy; Gregg C. Fonarow | Zendy; Brahmajee K. Nallamothu | Zendy; Dan J. Fintel | Zendy; Daniel E. Ford | Zendy; Li Zhou | Zendy; Sarah E. Daugherty | Zendy; Elizabeth Nauman | Zendy; Jennifer L. Kraschnewski | Zendy; Faraz S. Ahmad | Zendy; Catherine P. Benziger | Zendy; Kevin Haynes | Zendy; J. Greg Merritt | Zendy; Thomas S. Metkus | Zendy; Sunil Kripalani | Zendy; Kamal Gupta | Zendy; Raj C. Shah | Zendy; James C. McClay | Zendy; Richard N. Ré | Zendy; Carol Geary | Zendy; Brent C. Lampert | Zendy; Steven M. Bradley | Zendy; Sandeep Jain | Zendy; Hani Seifein | Zendy; Jeff Whittle | Zendy; Véronique L. Roger | Zendy; Mark B. Effron | Zendy; Giselle Alvarado | Zendy; Ythan Goldberg | Zendy; Jeffrey L. VanWormer | Zendy; Saket Girotra | Zendy; Peter Farrehi | Zendy; Kathleen M. McTigue | Zendy; Russell L. Rothman | Zendy; Adrian F. Hernandez | Zendy; W. Schuyler Jones | Zendy

Open Access

Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial

Author(s) -

Guillaume MarquisGravel,

Matthew T. Roe,

Holly R. Robertson,

Robert A. Harrington,

Michael Pencina,

Lisa G. Berdan,

Bradley G. Hammill,

Madelaine Faulkner,

Daniel Muñoz,

Gregg C. Fonarow,

Brahmajee K. Nallamothu,

Dan J. Fintel,

Daniel E. Ford,

Li Zhou,

Sarah E. Daugherty,

Elizabeth Nauman,

Jennifer L. Kraschnewski,

Faraz S. Ahmad,

Catherine P. Benziger,

Kevin Haynes,

J. Greg Merritt,

Thomas S. Metkus,

Sunil Kripalani,

Kamal Gupta,

Raj C. Shah,

James C. McClay,

Richard N. Ré,

Carol Geary,

Brent C. Lampert,

Steven M. Bradley,

Sandeep Jain,

Hani Seifein,

Jeff Whittle,

Véronique L. Roger,

Mark B. Effron,

Giselle Alvarado,

Ythan Goldberg,

Jeffrey L. VanWormer,

Saket Girotra,

Peter Farrehi,

Kathleen M. McTigue,

Russell L. Rothman,

Adrian F. Hernandez,

W. Schuyler Jones

Publication year - 2020

Publication title -

jama cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.108

H-Index - 63

eISSN - 2380-6591

pISSN - 2380-6583

DOI - 10.1001/jamacardio.2020.0116

Subject(s) - medicine , randomized controlled trial , aspirin , clinical endpoint , clinical trial , psychological intervention , stroke (engine) , medline , emergency medicine , intensive care medicine , physical therapy , nursing , mechanical engineering , political science , law , engineering

Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research